Patents for A61P 35 - Antineoplastic agents (221,099)
05/2002
05/30/2002US20020064823 Nucleotide sequences which code binding protein for use in human therapeutics and gene therapy
05/30/2002US20020064805 Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodies
05/30/2002US20020064786 Cancer diagnosis and therapy based on mutations in TGF-beta receptors
05/30/2002US20020064785 Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
05/30/2002US20020064784 Monitoring drug binding activity; obtain cells, generate mutation in cell genome, detect killing mutation, recover protein generated
05/30/2002US20020064522 Activated hemicellulose as active ingredient; use as anticancer agents
05/30/2002US20020064516 Pharmaceutical compositions comprising TGF-beta
05/30/2002US20020064515 Administering synergistic mixtures of immunostimulatory CpG oligonucleotides with unmethylated cytosine and guanine in given sequence, and immunopotentiating cytokines; treating tumors; contraceptive
05/30/2002CA2434760A1 Differentiated cells suitable for human therapy
05/30/2002CA2430113A1 Process for preparing aqueous extracts of plants and extracts so obtained
05/30/2002CA2430100A1 Antiangiogenic agents
05/30/2002CA2430037A1 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
05/30/2002CA2429976A1 Polysaccharide compound having immune stimulating activity
05/30/2002CA2429712A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/30/2002CA2429649A1 Drugs and foods improving the quality of life and process for producing the same
05/30/2002CA2429647A1 Use of thienopyrimidines
05/30/2002CA2429645A1 Use of pyrazolo[4,3-d]pyrimidines
05/30/2002CA2429630A1 Imidazole and benzimidazole caspase inhibitors and uses thereof
05/30/2002CA2429579A1 Truncated cd200
05/30/2002CA2429570A1 Pyrimidine derivatives
05/30/2002CA2429442A1 Aminothiazoles and their use as adenosine receptor antagonists
05/30/2002CA2429368A1 Production of stilbenes in transgenic plants and the method of producing thereof
05/30/2002CA2429328A1 Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases
05/30/2002CA2428470A1 Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage
05/30/2002CA2428191A1 Acid derivatives useful as serine protease inhibitors
05/30/2002CA2427661A1 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
05/30/2002CA2427444A1 3-arylindole derivatives and their use as cb2 receptor agonists
05/30/2002CA2427340A1 Cyp1b1 nucleic acids and methods of use
05/30/2002CA2427284A1 Antiinflammation agents
05/30/2002CA2427184A1 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
05/30/2002CA2426939A1 Cystoskeleton-associated proteins
05/30/2002CA2426601A1 Cyanoguanidine prodrugs
05/30/2002CA2398924A1 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
05/29/2002EP1209226A2 Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
05/29/2002EP1208852A1 Neuropeptide Y1 receptor binding compounds in the treatment and diagnosis of cancer
05/29/2002EP1208840A2 Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer
05/29/2002EP1208381A2 Proteins, genes and their use for diagnosis and treatment of breast cancer
05/29/2002EP1208380A2 Cancer associated antigens and uses therefor
05/29/2002EP1208234A1 Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
05/29/2002EP1208228A2 Differential gene expression in specific regions of the brain in neurodegenerative diseases
05/29/2002EP1208218A2 Methods and compositions for delivery of pharmaceutical agents
05/29/2002EP1208217A1 Antibody dependent enhancement (ade) of alphavirus infection
05/29/2002EP1208198A2 Egfh2 genes and gene products
05/29/2002EP1208197A1 Iren protein, its preparation and use
05/29/2002EP1208195A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/29/2002EP1208191A1 13 human colon and colon cancer associated proteins
05/29/2002EP1208116A2 Somatostatin analogs, radiolabelled derivatives thereof and their use
05/29/2002EP1208115A2 Feline interleukin-12 as an immune stimulant
05/29/2002EP1208113A2 17beta-acyl-alpha-propynyl-11beta-(cyclic amino)aryl steroids and their derivatives having antagonist hormonal properties
05/29/2002EP1208110A1 Antisense modulation of focal adhesion kinase expression
05/29/2002EP1208104A2 Tricyclic inhibitors of poly(adp-ribose) polymerases
05/29/2002EP1208103A2 Reverse-turn mimetics and methods relating thereto
05/29/2002EP1208097A2 Substituted oxoazaheterocyclyl compounds
05/29/2002EP1208096A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
05/29/2002EP1208092A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
05/29/2002EP1208088A2 Fluorene derivatives as integrin inhibitors
05/29/2002EP1208086A1 Benzamide formulation with histone deacetylase inhibitor activity
05/29/2002EP1208085A2 Benzanilides as potassium channel openers
05/29/2002EP1207906A1 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
05/29/2002EP1207904A1 New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
05/29/2002EP1207897A2 Pharmaceutical compositions containing tripeptides
05/29/2002EP1207890A2 Antiviral prodrugs
05/29/2002EP1207888A2 Use of paclitaxel and of steroid derivatives as aromatase inhibitors for the treatment of cancer
05/29/2002EP1207881A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient
05/29/2002EP1207876A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor
05/29/2002EP1207875A1 Pharmaceutically stable oxaliplatinum preparation for parenteral administration
05/29/2002EP1207863A2 New uses for potassium channel openers, such as the treatment of epilepsy
05/29/2002EP1207755A1 Methods of and compositions for inhibiting the proliferation of mammalian cells
05/29/2002EP1061812A4 Food products having enhanced cocoa polyphenol content and processes for producing same
05/29/2002EP0991637B1 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
05/29/2002EP0938329B1 Immunogenic tlp composition
05/29/2002EP0889971B1 Phosphatase modulator
05/29/2002DE10058663A1 Verwendung von Thienopyrimidinen Use of Thienopyrimidinen
05/29/2002DE10058662A1 Verwendung von Pyrazolo[4,3-d]pyrimidinen Use of pyrazolo [4,3-d] pyrimidines
05/29/2002DE10057976A1 Verfahren zur Herstellung von Pektinhydrolyseprodukten A process for producing pectin hydrolysis products
05/29/2002CN1351661A Compounds
05/29/2002CN1351656A Human liver progenitors
05/29/2002CN1351614A Human antibodies that bind human IL-12 and methods for producing
05/29/2002CN1351604A Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
05/29/2002CN1351602A New pharmaceutically active compounds
05/29/2002CN1351601A Heterocyclic compounds binding chemotactic factor receptor
05/29/2002CN1351594A Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
05/29/2002CN1351592A Acyl derivatives which treat VL4-4 related disorders
05/29/2002CN1351589A Vitamin D analogues and their pharmaceutical use
05/29/2002CN1351588A Inhibitors of LFA-l binding to ICAMs and uses thereof
05/29/2002CN1351587A Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors
05/29/2002CN1351498A Pyrrolotriazines inhibitors of kinases
05/29/2002CN1351494A Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations
05/29/2002CN1351490A Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
05/29/2002CN1351081A Human protein with cancer cell growth suppressing function and its coding sequence
05/29/2002CN1351080A Human protein with cancer call growth suppressing function and its coding sequence
05/29/2002CN1351079A Human protein with cancer cell growth suppressing function and its coding sequence
05/29/2002CN1350865A Keai Dan and its preparing process
05/29/2002CN1350861A Process for preparing health-care oral liquid to prevent cancer and delay sanility
05/29/2002CN1350853A Medicine for nourishing vital energy and blood and its preparing process
05/29/2002CN1350845A Medicine for treating chronic granulocytic leukemia
05/29/2002CN1350842A Lipoid and its application in medicines
05/29/2002CN1085672C Phospholipid derivatives of phosphono-carboxylic acids, prodn, and use as antiviral
05/29/2002CN1085666C 6-aryl pyrido (2,3-d) pyrimidines and naphthyridines for inhibiting protein tyro sine kinase medicated cellular proliferation
05/28/2002US6395886 Anticancer agents